MedPath

The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children

Not Applicable
Terminated
Conditions
Nausea
Interventions
Behavioral: Baxter Retching Faces (BARF) scale
Registration Number
NCT04678947
Lead Sponsor
Washington University School of Medicine
Brief Summary

In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding administration of anti-emetic medications will be reviewed.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Patients diagnosed with cancer of any kind.
  • Patients receiving inpatient chemotherapy at SLCH on the general pediatric oncology service
  • Patients admitted for a course of inpatient chemotherapy scheduled to last at least 24 hours and but no more than 7 days.
  • Patients who have received any prior cancer treatment, including radiation therapy, and/or surgery.
  • Patients ages 4 to 12 years of age.
  • Patient with a guardian who has the ability to understand English and the willingness to sign an IRB approved written informed consent document.
Exclusion Criteria
  • Any patient who is not undergoing inpatient chemotherapy on the general pediatric oncology service, including patients undergoing chemotherapy as conditioning for hematopoietic stem cell transplantation or other cellular therapy.
  • Any patient who is receiving their first cycle of inpatient chemotherapy (however, they can be included during a future cycle).
  • Any patient who is blind or unable to communicate by speaking or pointing.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BARF scaleBaxter Retching Faces (BARF) scale* Nursing staff (which may include patient technicians and nursing assistants) will use the scale to assess the patient's nausea for the entire duration of the admission. These assessments will take place in conjunction with vital sign monitoring, every 4 hours. The associated script will be read while the laminated scale is shown to the patient. * The nurse will then log the patient's response in the patient's electronic medical record
Primary Outcome Measures
NameTimeMethod
Doses of anti-emetic medication administered during inpatient chemotherapy admissions24 hours - 7 days (estimated)
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath